What is Elevian?
Elevian is a biotechnology company founded in 2017 and headquartered in Allston, Massachusetts. The company is dedicated to the development of novel therapeutics aimed at restoring youthful regenerative capacity. Its core mission is to create treatments that can address and potentially prevent a spectrum of age-related diseases by targeting fundamental biological processes associated with aging. This focus places Elevian at the forefront of the burgeoning longevity science sector, a field attracting substantial investment due to its vast therapeutic and commercial potential.
How much funding has Elevian raised?
Elevian has raised a total of $55M across 2 funding rounds:
Angel/Seed
$15M
Series A
$40M
Angel/Seed (2020): $15M with participation from Lauder Partners, Kizoo Ventures, SavEarth Fund, Western Technology Investment, For Good Ventures, BOLD Capital Partners, Longevity Fund companies, and Prime Movers Lab
Series A (2021): $40M led by BOLD Capital Group, John A Kuelbs Family Office, Leslie Ventures, and Prime Movers Lab
Key Investors in Elevian
Lauder Partners
Lauder Partners is an investment entity focused on the technology sector, investing directly in innovative companies and funds, primarily in the US and Canada. The firm seeks to support companies that are making radical innovations rather than incremental changes.
Western Technology Investment
Western Technology Investment (WTI) specializes in providing venture debt to assist startups in financing their growth while minimizing shareholder dilution. Since its inception in 1980, WTI has supported over 1,400 companies across various innovation sectors.
Longevity Fund companies
The Longevity Fund is a venture capital firm established in 2011, focused on funding companies that develop drugs for age-related diseases and longevity. The firm aims to support mission-oriented founders who are dedicated to creating innovative solutions in the longevity space.
What's next for Elevian?
With the recent major strategic investment, Elevian is poised to accelerate its research and development pipeline. The substantial capital infusion, part of its $55M in total financing, will likely be directed towards advancing its drug candidates through clinical trials and expanding its scientific team. The company's focus on regenerative medicine and the treatment of age-related diseases positions it for significant growth, potentially disrupting traditional healthcare paradigms. Future strategic partnerships and further funding rounds may be anticipated as Elevian progresses towards commercialization, aiming to translate its scientific breakthroughs into tangible patient benefits.
See full Elevian company page
